Novo Nordisk Stock Plummets Nearly 11% as CagriSema Underperforms Compared to Eli Lilly's Leading Weight Loss Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Source: aastocks
Novo Nordisk Stock Decline: Novo Nordisk's stock fell by 10.9% to DKK268.2 following disappointing trial results for its weight loss drug CagriSema, which showed less effectiveness compared to Eli Lilly's drug.
CagriSema Trial Results: In an 84-week trial, CagriSema resulted in a 20.2% weight reduction, while Eli Lilly's tirzepatide achieved a 23.6% reduction, contributing to a 4.5% increase in Eli Lilly's stock price.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
